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ABSTRACT 
 
Escitalopram and sertraline are among the most widely used drugs in the treatment of 
depression in Norway. Both drugs show substantial pharmacokinetic variability. Previous 
studies have indicated that the drug metabolising enzyme cytochrome P450 2C19 
(CYP2C19), which exhibits extensive variability in activity due to genetic polymorphism, 
is involved in the metabolism of escitalopram and sertraline. The aim of this thesis was 
therefore to investigate the impact of CYP2C19 genetics on the pharmacokinetic 
variability of escitalopram and sertraline in psychiatric patients. 
By use of data from therapeutic drug monitoring, CYP2C19 genotype was shown 
to be a major determinant of the pharmacokinetics of escitalopram. On average, dose-
adjusted serum concentration of escitalopram differed 9.7-fold between CYP2C19 poor 
metabolisers (PMs) and CYP2C19 ultrarapid metabolisers (UMs). Compared to 
CYP2C19 extensive metabolisers (EMs), the effect was more pronounced for CYP2C19 
PMs than for UMs (5.7-fold higher vs. 42% lower mean dose-adjusted serum 
concentration, respectively). It was further identified that CYP2C19, besides catalysing 
the well known N-desmethylation of escitalopram, was able to catalyse formation of the 
propionic acid metabolite. The differences in serum concentration of escitalopram 
between CYP2C19 genotypes were most likely caused by a combined effect on the two 
metabolic pathways. Genetic variability in CYP2C19 was an important determinant of the 
pharmacokinetics of sertraline as well. Dose-adjusted serum concentration of sertraline 
was on average 3.2-fold higher in CYP2C19 PMs compared to EMs, but did not differ 
between CYP2C19 UMs and EMs.  
The substantial differences in pharmacokinetics of escitalopram and sertraline 
between CYP2C19 genotypes are of potential importance for the clinical response during 
treatment with these drugs. CYP2C19 UMs might constitute a subgroup of patients at 
increased risk of therapeutic failure, whereas CYP2C19 PMs are possibly at higher risk of 
dose-dependent side effects. Although further studies are needed to investigate the value 
of CYP2C19 genotyping in the prevention of therapeutic failure and side effects during 
treatment with escitalopram and sertraline, the findings of the present thesis may provide 
a fundament for individual dosing to limit variability in exposure of these drugs. 
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1 INTRODUCTION 
Individual variability in drug response is a major challenge in modern medicine.1 Treating 
patients with a given drug generally implies lack of effect in some patients while others 
experience side effects. The reason for this is multifactorial, and the drug response is 
determined by both the drug concentration at its site of action (pharmacokinetics) and the 
interaction of the drug with its target protein, i.e. receptor, transporter or enzyme 
(pharmacodynamics) (Figure 1). 
Besides being dependent of the drug dose, concentration of a drug at its site of 
action is determined by pharmacokinetic processes, i.e. absorption, distribution, 
metabolism and excretion of the drug. For a specific drug, variability in pharmacokinetic 
processes could be due to patient specific factors (e.g. genetics, co-morbidity and age), 
and/or environmental factors (e.g. smoking, diet and drug-drug interactions), and implies 
that administration of the same drug dose to different patients results in several-fold 
difference in drug concentrations.1-4 It is generally difficult to measure the concentration 
of a drug at its site of action, for instance in the brain. Thus, as most drugs are distributed 
to their site of action via the systemic circulation, drug concentration in plasma/serum 
(‘systemic exposure’) is used as a surrogate measurement reflecting the drug 
concentration at its site of action. 
 
Clinical
response
Drug
target
Absorption
Distribution
Metabolism
Excretion
Concentration
Dose
 
 
Figure 1 Clinical response during drug treatment depends on  
pharmacokinetics (light blue) and pharmacodynamics (dark blue). 
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1.1 Drug metabolism 
The majority of drugs are foreign substances to the body. Natural defense mechanisms, 
which have evolved to avoid foreign substances in the environment causing harm to the 
body, will seek to limit drug exposure. Most drugs are lipophilic compounds, and 
elimination of many drugs therefore involves biotransformation (metabolism) into more 
hydrophilic compounds (metabolites) to enable excretion in urine and bile. Metabolic 
reactions are classified as either phase I or phase II reactions. Whereas phase I reactions 
introduce or expose a functional group on the drug, for example a hydroxyl or amino 
group, phase II reactions generate highly polar compounds by conjugation of the drug or 
phase I metabolite with endogenous compounds, for example glucuronic acid or sulphate. 
Multiple competitive reactions and sequential steps may take place and metabolism of a 
drug often leads to the formation of a number of different metabolites. Many metabolites 
are without therapeutic impact due to low concentrations or lack of affinity for targets 
molecules, whereas other metabolites are of importance for the therapeutic effect and/or 
toxicity of the drug treatment. As the formation of metabolites shows considerable 
variability, individual differences in metabolite pharmacokinetics could be even greater 
than for the parent drug.5;6 
Metabolic reactions are usually enzyme-catalysed. The cytochrome P450 (CYP) 
enzymes is a superfamily comprising 57 related enzymes (isoenzymes).7 Some of these 
are importantly involved in the phase I metabolism of a large number of drugs.6;8 The 
superfamily of CYP enzymes is categorised into families and subfamilies based on 
similarity in amino acid sequence. These are named by the root symbol CYP (cytochrome 
P450), followed by a number designating the family, e.g. CYP2 (>40% similarity in 
amino acid sequence), a letter denoting the subfamily, e.g. CYP2C (> 55% similarity in 
amino acid sequence), and a final number indicating the specific isoenzyme, e.g. 
CYP2C19. The gene encoding the enzyme is referred to by placing the enzyme name in 
italics, i.e. CYP2C19.9;10  
CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 play a prominent role in 
drug metabolism.6;8 These isoenzymes have distinct, but overlapping, substrate specificity 
and catalyse a diversity of reactions, including dealkylation, hydroxylation, oxidation and 
deamination.6 The CYP enzymes are located in the endoplasmatic reticulum, and are 
abundantly expressed in cells in the liver and intestine.11 The activity (phenotype) of the 
CYP enzymes is influenced by patient specific factors (e.g. genetics, hormone status and 
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co-morbidity) and environmental factors (e.g. smoking, diet and drug-drug-interactions). 
Variable phenotype of CYP enzymes is a source of individual differences in the 
pharmacokinetics of many drugs.1-4 For CYP2C9, CYP2C19 and CYP2D6, phenotype is 
distinctly correlated with the genotype, whereas this is not the case for CYP3A4 and 
CYP1A2.4  
1.2 Genetic polymorphism in cytochrome P450 
The existence of genetic polymorphism affecting CYP enzymes was first recognised for 
CYP2D6 and CYP2C19 in the 1970s.12-14 It was observed that a subgroup of individuals 
exhibited impaired metabolism of certain drugs, i.e. debrisoquine and sparteine 
(CYP2D6) and S-mephenytoin (CYP2C19). The bimodality was later shown to be caused 
by alleles encoding defective enzyme activity (‘defective alleles’), which in its 
homozygous presence gave rise to the poor metaboliser (PM) phenotype, i.e. individuals 
totally deficient of enzyme activity.15 Later, genetic variability that affects enzyme 
activity has been identified for several CYP enzymes,16 but the association between 
genotype and phenotype is greatest for CYP2D6 and CYP2C19.4 
1.2.1 CYP2D6 
About 80 CYP2D6 variant alleles, indicated by an asterisk and an Arabic numeral (e.g. 
CYP2D6*4), have so far been described.16 Estimated frequencies of the most common 
CYP2D6 variant alleles in different ethnic groups are presented in Table 1. Defective 
CYP2D6 alleles are most common in Caucasian populations, where 5-10% express the 
PM phenotype.17 Amplification of functional CYP2D6 alleles (CYP2D6*1xN, *2xN, N=2-
13)16 gives rise to an ultrarapid CYP2D6 phenotype (CYP2D6 UMs)18 which is common 
in Hispanic (~7%) and certain African populations whereas the incidence is less than 2% 
in northern Europe.17;19 Most remaining Caucasians carry one or two functional gene 
copies (*1 or *2), being heterozygous or homozygous extensive metabolisers (CYP2D6 
EMs).17;19 The frequencies of defective CYP2D6 alleles, and hence the PM phenotype, are 
low in African and East Asian populations.17 However, high occurrence of alleles 
encoding decreased (‘intermediate’) enzyme activity (*10 and *17), implies an overall 
lower CYP2D6 activity in these populations than in Caucasians.15;17 
A number of clinically important drugs, including antidepressants, antipsychotics, 
beta blockers, and antiarrhythmics, are metabolised by CYP2D6.20;21 Examples where 
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clinical response is associated with CYP2D6 genotype are haloperidol, 22 risperidone,23 
metoprolol,24;25 and codeine.26 
Table 1 Estimated frequencies of common CYP2D6 variant alleles in different ethnic groups.
CYP2D6 allele Activity Population, estimated allele frequencies (%) 
  
African African American Caucasian
b East Asian 
*3 None 0.1 0.4 1.8  
*4 None 3.0 7.5 19.9 1.0 
*5 None 2.9 6.4 4.5 5.5 
*6 None   1.0  
*9 Decreased 0  2.0  
*10 Decreased 5.0 5.1 2.3 46.9 
*17 Decreased 22.3 21.6 0.1  
*41 Decreased   7.9a  
*1xN /*2xN Increased 1.6-28.3a, c  1.2 1.0 
Estimates are weighted for population size in studies reviewed by Bradford et al.,17 asupplemented with data from  
Sistonen et al.19 and/or Raimundo et al.27 bGerman and US populations. cRange presented due to considerable differences 
between populations. Estimates are based on data from >350 subjects. 
1.2.2 CYP2C19 
For CYP2C19, seven defective alleles have so far been identified, i.e. CYP2C19*2-*8.28-34 
CYP2C19*2 and *3, characterised by single nucleotide polymorphisms in coding regions, 
account for a majority of the defective CYP2C19 alleles.33;34 Their distribution in 
different ethnic groups is summarized in Table 2. Both *2 and *3 are common in eastern 
Asia and give rise to an incidence of CYP2C19 PMs of 13-23% in these populations.15 
The *2 allele is the most frequent defective CYP2C19 allele in Caucasian populations, 
where approximately 3% are CYP2C19 PMs.15;35 Noteworthy, about 80% of the people 
living on the islands of Vanuatu are reported to be CYP2C19 PMs.36  
 
Table 2 Estimated frequencies of common CYP2C19 variant alleles in different ethnic groups.
CYP2C19 allele Activity Population, estimated allele frequencies (%) 
  African African American Caucasian Chinese Japanese 
*2 None 15.9 18.6 14.7 30.0 29.4 
*3 None 0.8 0.1 0.04 5.1 12.2 
*17 Increased 17.9a  22.8 0.6-4.4b 1.3 
Estimates are weighted for population size in studies reviewed by Xie and co-workers35;37;38 supplemented with  
studies in healthy subjects.39-47 aEthiopians. bRange presented due to discrepancies between the studies.43;45;46  
Estimates are based on data from  190 subjects. 
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Genetic variability has also been identified in the regulatory regions of 
CYP2C19,46;48;49 and recently, a variant allele encoding increased CYP2C19 activity was 
identified (CYP2C19*17).43 The higher enzyme activity was ascribed to a single 
nucleotide polymorphism (-806C>T) in the promoter region causing increased 
recruitment of transcription factor(s) and thereby higher levels of functional CYP2C19 
enzyme.43 The CYP2C19*17/*17 genotype has been suggested to imply an ultrarapid 
CYP2C19 phenotype (CYP2C19 UM), but its impact on in vivo clearance of probe 
substrates seems to be variable.43;50-52 A high frequency of the CYP2C19*17 allele has 
been reported in Caucasian and African populations (Table 2),43;47 indicating an 
incidence of CYP2C19 UMs of about 3-7% in these populations. In contrast, *17 seems 
to be rare in Asian populations.43-46 Other CYP2C19 variant alleles have been associated 
with reduced enzyme activity in vitro (*9, *10 and *12)48 or a slower CYP2C19 
phenotype in certain individuals (*16, *26),53;54 but their contribution to overall 
variability in CYP2C19 phenotype remains to be established.  
CYP2C19 is involved in the metabolism of several drugs on the market, including 
proton pump inhibitors and antidepressants.4;8;55 Selected drugs metabolised by CYP2C19 
are listed in Table 3. Examples where CYP2C19 genetics has been associated with 
clinical response are proton pump inhibitors56 and the antiplatelet agent clopidogrel.57-59 
Table 3 Selected drugs metabolised by CYP2C19.4;8;55 
Antidepressants Proton pump inhibitors Others 
amitriptyline 
citalopram 
clomipramine 
escitalopram 
imipramine 
moclobemide 
sertraline 
trimipramine 
lanzoprazole 
omeprazole 
pantoprazole 
rabeprazole  
 
carisoprodol  
clopidogrel 
cyclophosphamide 
diazepam 
proguanil 
phenobarbitone 
phenytoin 
S-mephenytoin 
1.3 CYP genotyping and therapeutic drug monitoring 
Traditionally, physicians adjust drug therapy according to subjective or objective 
monitoring of clinical response. However, monitoring of clinical effect and possible side 
effects is a challenging task for many drugs. Suboptimal use of drugs is a common source 
of morbidity and mortality, and drug-related problems are estimated to account for 3-7% 
of all hospitalisations,60 leading to increased burden of disease for the individual patient 
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and large costs to the society. CYP genotyping and therapeutic drug monitoring of serum 
concentration (TDM) are objective tools which could be used for individualisation and 
optimisation of drug therapy.61 Based on the genotype-phenotype relationship for a given 
drug, the dose can be adjusted according to expected exposure in the individual 
patient.62;63 However, besides genotype, the CYP phenotype is affected by physiological 
and environmental factors.2;3 TDM captures the majority of this variability, and can be 
applied regardless of genotype-phenotype relationship for a given drug. In addition, TDM 
provides an objective assessment of patient compliance. 
Optimisation of drug treatment for psychiatric disorders is particularly 
complicated due to lack of objective measurement of response, slow onset of effects, high 
degree of placebo- and non-response, and occurrence of side effects which mimic 
symptoms of the underlying diseases.64;65 Furthermore, many psychoactive drugs show 
extensive pharmacokinetic variability, partly because they are metabolised by 
polymorphic CYP enzymes.8 Prolonged hospitalisation and higher treatment costs are 
reported for psychiatric patients with a PM/UM phenotype compared to EMs,66;67 
probably due to increased incidence of side effects and therapeutic failure in these 
patients.22;23;66;68;69 The potential benefit of TDM and CYP genotyping for antidepressive 
treatment was illustrated in a study by Kootstra-Ros et al.70 TDM showed that more than 
half of the patients possessed serum concentrations outside the therapeutic ranges, and the 
CYP genotyping was reported to clarify medication-related problems in individual 
patients, e.g. occurrence of side effects and low serum concentrations despite use of 
standard drug doses. For more than 60% of the patients advices were provided to the 
general practitioner regarding current and/or future medication regimens.70 Thus, within 
the psychiatric field, TDM and CYP genotyping appear to be valuable tools to aid 
individualisation, optimisation and evaluation of drug therapy.61;68;71-74 
1.4 Selective serotonin reuptake inhibitors 
Depression is characterised by persistent low mood, loss of interest and pleasure, and 
symptoms like decreased appetite, insomnia and fatigue.75 An association between 
depressive symptoms and the ability of certain drugs to affect monoaminergic 
transmission was observed during the 1950s and 60s. This led to the monoamine theory, 
which hypothesised that depression was caused by functional deficit of certain 
monoamine neurotransmitters (serotonin and noradrenalin) in the brain.76;77 The tricyclic 
antidepressants (TCAs), which increase noradrenergic and serotonergic transmission by 
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inhibition of transporters in the nerve terminals, were the primary drugs for treatment of 
depression throughout the 1960s and 70s.78 However, troublesome side effects and 
toxicity due to their affinity for ion channels and neurotransmitter receptors prompted the 
search for antidepressants targeting the neurotransmitter transporters more specifically. 
This led to the introduction of the selective serotonin reuptake inhibitors (SSRIs) in the 
1980s.64;78 They are effective in the treatment of depression, but without the serious 
cardiac side effects, seizures and risk of death from overdose associated with the 
TCAs.64;65 
Today the SSRIs, comprising fluoxetine, fluvoxamine, sertraline, paroxetine, 
citalopram and escitalopram, are the first line treatment of depression, and are also widely 
used in the treatment of other psychiatric disorders, for example anxiety and eating 
disorders.64;65 The SSRIs selectively inhibit the serotonin transporter and produce an 
immediate increase in serotonergic transmission.64 However, their effect on depression 
takes several weeks to develop, and it is therefore believed that long-term effects 
secondary to the increased serotonergic transmission are of importance for the 
antidepressive effect of the SSRIs, for example downregulation of serotonin receptors.64 
The substantial increase in the use of antidepressants during the last 20 years is primarily 
due to increased use of the SSRIs, and according to the Norwegian Prescription Database 
about 4% of the Norwegian population had a SSRI prescription dispensed in 2008.79 
Based on efficacy, tolerability, drug-drug interaction profile and cost, citalopram, 
escitalopram and sertraline are often recommended when starting treatment of 
depression.80 In line with this, these agents accounted for well over 80% of the daily 
doses of SSRIs sold in Norway in 2008.81 
1.4.1 Pharmacology of citalopram, escitalopram and sertraline 
Citalopram (1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-
5-carbonitrile), which was introduced to the marked in 1989, is a racemic compound. The 
pharmacological activity as serotonin reuptake inhibitor resides in the S-enantiomer 
(escitalopram, S-citalopram)82 whereas the R-enantiomer is actually reported to inhibit 
the effect of the S-enantiomer.83 Thus, escitalopram (S-citalopram) was introduced as an 
individual drug in 2001. 
Escitalopram allosterically inhibits the serotonin transporter84 and is the most 
selective reuptake inhibitor among the SSRIs, exhibiting low inhibition of both 
noradrenalin and dopamine transporters.85 Escitalopram undergoes phase I metabolism to 
11 
N-desmethyl, N-didesmethyl, N-oxide, and propionic acid escitalopram (Figure 2).86;87 
The N-oxide and N-desmethylated metabolites exhibit weaker inhibition of serotonin 
reuptake in vitro88 and are present at lower plasma concentrations than the parent 
compound at steady state.86;89 Thus, the therapeutic effect of escitalopram treatment is 
mainly ascribed to the parent compound. In vitro studies have shown that CYP3A4, 
CYP2C19 and CYP2D6 are able to catalyse formation of N-desmethyl escitalopram, 
whereas formation of the N-didesmethyl and N-oxide metabolites seems to be catalysed 
primarily by CYP2D6.90;91 In vivo studies have indicated that CYP2C19 is involved in 
the metabolic clearance of escitalopram, whereas CYP2D6 and CYP3A4 seem to play a 
minor role.92-99 The metabolites, as well as unmetabolised escitalopram, are recovered in 
urine, partly as glucuronide conjugates.86;100;101 
 
Escitalopram
N-desmethyl
escitalopram
N-didesmethyl
escitalopram
N-oxide 
escitalopram
Propionic acid
escitalopram 
(SCIT PROP)
 
Figure 2 Phase 1 metabolites of escitalopram.86;87 
 
Sertraline ((1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-
amine) was introduced to the market in 1990, and next to citalopram/escitalopram, it 
shows the lowest inhibition of noradrenalin uptake among the SSRIs.85 Its dopamine 
uptake blocking effects is however marked compared to other SSRIs,85 and dopaminergic 
effects are reported in patients treated with sertraline.65;102;103 The primary metabolic 
pathway of sertraline is suggested to be N-desmethylation followed by deamination to the 
sertraline ketone, which is hydroxylated prior to elimination in urine (conjugated to 
glucuronic acid) and in faeces (Figure 3).104-107 However, direct deamination of sertraline 
to sertraline ketone and formation of a carbamic acid and a N-hydroxy metabolite have 
also been reported.105;108 Plasma concentration of N-desmethyl sertraline is higher than 
that of sertraline at steady state,104;109 and comparable brain/plasma ratios have been 
reported for the N-desmethylated metabolite and the parent drug in rats.105 However, the 
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potency of N-desmethyl sertraline to inhibit serotonin uptake is less than 15% compared 
to that of sertraline,110-113 and the antidepressive effect is therefore assumed to be mainly 
attributable to the parent compound. However, regarding inhibition of noradrenalin and 
dopamine uptake, N-desmethyl sertraline shows potency up to 100% compared to the 
parent drug.110-113 Multiple CYP enzymes are able to catalyse the N-desmethylation of 
sertraline in vitro, including CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and 
CYP3A4.108;114-116 In vivo studies have indicated that CYP2C19117 and CYP3A4118;119 are 
both involved in the metabolism of sertraline, but not CYP2D6.120 
 
N-hydroxy 
sertraline
Sertraline
carbamic acid
Sertraline
N-desmethyl 
sertraline
Sertraline 
ketone
Sertraline alpha- 
hydroxy ketone
N
OH
O
OH
N H 2
NO
OH
Cl
Cl
NH O
 
Figure 3 Phase I metabolites of sertraline.104-107 
1.4.2 Dose-effect relationship 
In registration studies with SSRIs, response rates are reported not to increase with 
dose.121;122 One possible explanation for this apparently flat dose-response curve could be 
the use of fixed doses and the last observation carried forward approach in these studies. 
As described by Preskorn et al. this may mask a better effect of the higher drug doses.123 
Noteworthy, Bech et al.124 revealed a clear dose-response relationship in the 
subpopulation of severely depressed patients in a fixed dose study with escitalopram,122 
possibly due to lower rates of placebo response compared to less severely depressed 
patients.125 Furthermore, flexible dosing studies have been reported to show advantage of 
higher doses of SSRIs.64 Regarding side effects of SSRIs, it seems to be a more consistent 
dose-dependency, and nausea, insomnia, and sexual dysfunction are common side effects 
reported to attenuate with dose reduction.64;121;122 Thus, despite some uncertainty 
regarding the dose-effect relationship, individual dose titration is recommended to 
optimise clinical effect and limit side effects of SSRIs.64;65 
13 
Serum concentrations of escitalopram and sertraline are reported to vary up to 40-
fold among patients treated with the same dose,109;126 but little is known about the 
relationship between serum concentration and therapeutic outcome of treatment with 
these drugs.74 However, the fact that drug dosage is recognised as a variable of 
importance for the therapeutic outcome of SSRIs, implies that drug concentration is also a 
relevant outcome variable. Thus, the extensive variability in the pharmacokinetics of 
escitalopram and sertraline is likely to be a reason for differences in clinical response 
among patients treated with these drugs. To enable better individualisation of treatment 
with escitalopram and sertraline, it is therefore important to identify the factors 
contributing to their extensive pharmacokinetic variability. 
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2 AIM OF THESIS 
 
Based on the substantial variability in the pharmacokinetics of escitalopram and 
sertraline, two of the most frequently used antidepressants in Norway, the overall 
objective of this thesis was to investigate the impact of CYP2C19 genetics on the 
pharmacokinetic variability of these drugs in psychiatric patients. 
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3 SUMMARY OF RESULTS 
 
Paper I 
‘Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio 
of racemic citalopram and escitalopram (S-citalopram)’ 
In this study, the impact of heterozygosity for defective CYP2C19 alleles on serum 
concentration of racemic citalopram and escitalopram was investigated based on TDM 
data and CYP genotype in 83 patients. For both racemic citalopram and escitalopram, 
median dose-adjusted serum concentration and parent drug/metabolite ratio were from 
1.6- to 2.0-fold higher in the subgroups of patients heterozygous for defective CYP2C19 
alleles compared to the subgroups homozygous for CYP2C19*1 (CYP2C19 EMs) 
(p<0.01). The observed differences were somewhat larger for escitalopram than for 
racemic citalopram. Higher median non-dose-corrected serum concentration was 
observed in the subgroups of patients heterozygous for defective alleles than in CYP2C19 
EMs for both racemic citalopram and escitalopram (2.2-fold; p=0.066, and 2.5-fold; 
p<0.01, respectively), indicating that the impaired metabolic clearance in this patient 
subgroup was not compensated for by dose reductions in clinical practice. 
The observed differences in median dose-adjusted serum concentration and parent 
drug/metabolite ratio of citalopram and escitalopram between heterozygous carriers of 
defective CYP2C19 alleles and EMs showed that considerable pharmacokinetic 
variability within patients expressing functional CYP2C19 enzyme was due to 
heterozygosity for defective CYP2C19 alleles. 
Paper II 
‘Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in 
psychiatric patients’ 
In this study, the impact of the CYP2C19*17 allele on serum concentration of 
escitalopram and N-desmethyl escitalopram was quantified, and compared with defective 
CYP2C19 alleles. The study included TDM data and CYP genotype from 166 patients. 
When available, multiple serum concentration measurements from the same individual 
were included. Homozygous carriers of the CYP2C19*17 allele (CYP2C19 UMs) (n=7 
patients) obtained significantly lower mean dose-adjusted steady state serum 
concentration (Css) of escitalopram (42%) compared to the subgroup of CYP2C19 EMs 
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(p<0.01). The CYP2C19*17 allele had a less pronounced effect than the defective 
CYP2C19 alleles, which in homozygous carriers (CYP2C19 PMs) (n=6 patients) resulted 
in a 5.7-fold higher Css of escitalopram compared to CYP2C19 EMs (p<0.001). Overall, 
Css of escitalopram differed 9.7-fold between the outmost CYP2C19 genotypes. There 
were no consistent differences in Css of N-desmethyl escitalopram among the CYP2C19 
genotype subgroups. The study also revealed a gender difference and an effect of 
CYP2D6 genetics, with higher Css of both escitalopram and N-desmethyl escitalopram in 
females (26% and 40%, respectively, p<0.01) and in carriers of defective CYP2D6 alleles 
(28% and 12%, respectively, p<0.05).  
The observed 9.7-fold range in Css of escitalopram across different genotypes 
shows that CYP2C19 is a major determinant of the pharmacokinetics of escitalopram. 
The substantial differences in Css are of potential importance for the clinical response to 
treatment with escitalopram. CYP2C19 UMs might constitute a subgroup of patients at 
increased risk of therapeutic failure, whereas CYP2C19 PMs might be at higher risk of 
dose-dependent side effects, or potentially improved antidepressive effect. 
Paper III 
‘Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 
genotype in psychiatric patients’ 
In this study, the impact of genetic variability in CYP2C19 on serum concentration of 
sertraline and N-desmethyl sertraline was investigated based on TDM data and CYP 
genotype from 121 patients. Multiple serum concentration measurements from the same 
individual were included when available. Carriers of defective CYP2C19 alleles obtained 
significantly higher Css of both sertraline and N-desmethyl sertraline compared to 
CYP2C19 EMs. In CYP2C19 PMs (n=5 patients), the effect was expressed as a 3.2- and 
4.5-fold higher Css of sertraline (p<0.01) and N-desmethyl sertraline (p<0.001), 
respectively. There was no detectable effect of the CYP2C19*17 allele on Css of sertraline 
or N-desmethyl sertraline. Patients aged  70 years on average obtained 1.8- and 2.0-fold 
higher Css of sertraline and N-desmethyl sertraline, respectively (p<0.001). 
The differences in Css between CYP2C19 EMs and PMs show that CYP2C19 
metabolism is an important determinant of the pharmacokinetics of both sertraline and N-
desmethyl sertraline. The differences in Css are of possible relevance for the clinical 
response to sertraline. 
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Paper IV 
‘Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro’ 
This combined in vitro/in vivo study aimed to investigate to what extent CYP2C19-
catalysed clearance of escitalopram (S-citalopram) was due to a metabolic pathway 
different from N-desmethylation, and to identify the product(s) of this possible alternative 
pathway. Metabolism of escitalopram was investigated in vitro by the use of recombinant 
microsomes expressing CYP2C19. It was identified that CYP2C19, besides catalysing the 
well known N-desmethylation, was able to catalyse formation of the propionic acid 
metabolite of escitalopram (SCIT PROP). Formation of SCIT PROP accounted for 35% 
of total CYP2C19-mediated clearance of escitalopram in vitro, whereas 51% was due to 
N-desmethyl escitalopram formation. 
Analysis of six serum samples from patients treated with escitalopram showed 
that, relative to CYP2C19 EMs, Css of SCIT PROP and mean SCIT PROP/escitalopram 
ratio was lower in the two PMs (0.48 and 0.32, respectively) and higher in the two UMs 
(1.42 and 2.69, respectively). Thus, CYP2C19 seemed to be importantly involved in the 
in vivo formation of this metabolite. This indicates that the differences in Css of 
escitalopram between CYP2C19 genotypes (Paper I, II and IV) were caused by a 
combined effect on formation of N-desemethyl escitalopram and SCIT PROP. 
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4 DISCUSSION 
 
In the present work, genetic variability in CYP2C19 was shown to be an important 
determinant of the pharmacokinetics of escitalopram and sertraline (Paper I-IV), two of 
the most widely used antidepressants in Norway. The several-fold differences in mean 
dose-adjusted serum concentrations between various CYP2C19 genotypes are of potential 
importance for the clinical response during treatment with these drugs. 
4.1 Impact of CYP2C19 genetics on the pharmacokinetic variability of 
escitalopram 
Mean dose-adjusted steady state serum concentration (Css) of escitalopram differed 9.7-
fold between patients carrying different CYP2C19 genotypes, showing that genetic 
variability in CYP2C19 is a major determinant of Css of escitalopram (Paper II). Sorted 
from the lowest to the highest Css, the CYP2C19 genotypes arranged as follows: 
CYP2C19*17/*17<CYP2C19*1/*17<CYP2C19*1/*1<CYP2C19*17/def<CYP2C19*1/def
<CYP2C19def/def (def = defective allele). Patients homozygous for defective CYP2C19 
alleles (CYP2C19 PMs) obtained 5.7-fold higher Css of escitalopram compared to patients 
carrying the CYP2C19*1/*1 genotype (CYP2C19 EMs). Impaired elimination of 
escitalopram in CYP2C19 PMs is consistent with other studies,92;93;96;97 but the nearly 6-
fold higher Css in PMs was a considerably larger effect than the 1.7- to 1.9-fold higher 
area under the plasma concentration versus time curve (AUC) reported by Noehr-Jensen 
et al. and Herrlin et al.92;93 In the study by Noehr-Jensen et al.92 the participants were 
classified based on phenotyping with omeprazole, and confirmative genotyping showed 
that both the CYP2C19 EM and PM subgroup included carriers of the CYP2C19*1/*2 
genotype. This is possibly a reason for the less pronounced difference in that study 
compared to the study presented in Paper II. See section 4.6 Methodological 
considerations, for further discussion. 
Patients carrying the CYP2C19*17/*17 genotype (CYP2C19 UMs) obtained 42% 
lower Css of escitalopram compared to CYP2C19 EMs. This was in accordance with the 
study by Sim et al. reporting that the CYP2C19*17 allele encodes increased CYP2C19 
activity,43 but two other studies with escitalopram have not found a significant effect of 
CYP2C19*17.96;127 Whereas Ohlsson Rosenborg et al. observed a non-significantly 21% 
lower AUC of escitalopram in CYP2C19 UMs compared to CYP2C19 EMs,127 Jin et al. 
reported no differences in oral clearance between CYP2C19 UMs and a combined group 
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of CYP2C19*1/*1 and *1/*17 carriers.96 Again, different design of the studies and limited 
number of CYP2C19 UMs (n=5-7) are possible reasons for inter-study discrepancies 
regarding the effect on escitalopram pharmacokinetics. Thus, it is uncertain to which 
degree the CYP2C19 UM phenotype affects the systemic exposure of escitalopram. 
However, from the findings in Paper II, it could not be excluded that patients 
homozygous for CYP2C19*17 are at higher risk of therapeutic failure.  
In Paper I and Paper II it was shown that Css of escitalopram also differed between 
CYP2C19 EMs and patients heterozygous for CYP2C19 variant alleles. The difference 
between the CYP2C19 EMs and carriers the CYP2C19*1/def genotype in Paper I was 
somewhat larger for escitalopram than for racemic citalopram (2.0- vs. 1.6-fold, 
respectively). Similarly, previous studies have reported that CYP2C19 is of greater 
importance for the metabolism of the S-enantiomer compared to the R-
enantiomer.90;93;95;128 Inclusion of genotyping of the CYP2C19*17 allele in the study 
presented in Paper II resulted in three subgroups of patients carrying heterozygous 
mutations. Compared to CYP2C19 EMs, Css of escitalopram was higher in the 
CYP2C19*1/def subgroup (1.9-fold, p<0.001), whereas non-significantly lower Css was 
observed in the subgroup of patients carrying the CYP2C19*1/*17 genotype (0.87-fold, 
p=0.13). Besides verifying the importance of heterozygosity for defective CYP2C19 
alleles revealed in the study presented in Paper I, this confirms that CYP2C19*17 has a 
less pronounced impact on the Css of escitalopram compared to the defective CYP2C19 
alleles. 
The bioavailability of escitalopram is reported to be about 80%,97;129 implying that 
impaired metabolism potentially affects bioavailability only to a minor extent. Thus the 
higher Css associated with defective CYP2C19 alleles (Paper II) is primarily due to 
reduced clearance. However, the increased CYP2C19 activity in UMs might imply higher 
first pass metabolism of CYP2C19 substrates in these patients.130 Therefore, the lower Css 
of escitalopram observed in CYP2C19 UMs may be due to both higher clearance and 
lower bioavailability. 
Despite previous in vitro studies reporting that CYP2C19 catalyses the N-
desmethylation of escitalopram,90;91;128 there were no consistent differences in Css of N-
desmethyl escitalopram among the CYP2C19 genotype subgroups in Paper II. This is in 
line with other pharmacogenetic92;93;127 and drug-drug interaction studies95;131 where 
systemic exposure of N-desmethyl escitalopram has been reported to be largely 
unaffected by differences in CYP2C19 activity. In Paper II, it was therefore stated that 
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CYP2C19 appears to be of minor importance for the formation of N-desmethyl 
escitalopram. However, from Figure 1 in Paper II it appears that the N-desmethyl 
escitalopram/escitalopram ratio was lower in CYP2C19 PMs compared to EMs. This 
reflects a lower formation rate of N-desmethyl escitalopram in CYP2C19 PMs. However, 
the further metabolism of N-desmethyl escitalopram to N-didesmethyl escitalopram is 
assumed to be independent of CYP2C19 (Paper IV).90;91 The similar Css of N-desmethyl 
escitalopram in different CYP2C19 genotype subgroups therefore indicates that a 
comparable amount of the administered dose is eliminated by N-desmethylation 
regardless of CYP2C19 activity. This is consistent with the study of Herrlin et al.93 
reporting only a slightly lower recovery of N-desmethylated metabolites of escitalopram 
in urine from CYP2C19 PMs compared to EMs. Thus, CYP2C19 genotype affects the 
rate of N-desmethylation, whereas the amount of escitalopram finally eliminated as N-
desmethylated metabolites appears to be unaltered. 
Based on the low urinary recovery of escitalopram as N-desmethylated 
metabolites in CYP2C19 EMs93 and the limited contribution from CYP2C19 to the N-
desmethylation of escitalopram in vitro,90;91;128 the lower rate of N-desmethylation in 
CYP2C19 PMs could not alone account for the nearly six-fold difference in Css of 
escitalopram between CYP2C19 EMs and PMs in Paper II. Thus, CYP2C19 appeared to 
be involved in metabolic pathways of escitalopram besides the N-desmethylation. This 
was investigated in the in vitro study presented in Paper IV, which identified that 
CYP2C19 is able to catalyse formation of the propionic acid metabolite of escitalopram 
(SCIT PROP). SCIT PROP accounted for one third of the substrate loss of escitalopram 
in recombinant CYP2C19 microsomes. In comparison, about one half of the substrate loss 
was due to formation of N-desmethyl escitalopram. Thus, more than 80% of the 
CYP2C19-mediated clearance of escitalopram in vitro was explained by formation of 
these two metabolites (Figure 4). 
Although it is well known that escitalopram is deaminated to SCIT PROP in 
vivo,87;95;132;133 the in vitro study presented in Paper IV appears to be the first to identify 
that CYP2C19 is able to catalyse the formation of this metabolite. Analysis of serum 
samples from a limited number of CYP2C19-genotyped patients treated with escitalopram 
showed that Css of SCIT PROP and mean SCIT PROP/escitalopram ratio was lower in 
two CYP2C19 PMs and higher in two UMs relative to two EMs (Paper IV). This appears 
to be consistent with data presented for racemic citalopram in a previous study,134 and 
indicates a key role of CYP2C19 for the in vivo formation of SCIT PROP. Thus, it seems 
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that the difference in clearance of escitalopram between CYP2C19 genotypes is caused by 
a combined effect on the formation of N-desmethyl escitalopram and SCIT PROP. 
Identification of this novel CYP2C19-mediated metabolic pathway of escitalopram may 
therefore explain the larger effect of defective CYP2C19 activity on systemic exposure of 
escitalopram than what is accounted for by the impaired N-desmethylation. 
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SCIT PROP was also detected in CYP2C19 PMs (Paper IV). This may be explained by 
previous studies reporting that monoamine oxidase is able to catalyse formation of this 
metabolite in vitro.135-137 However, the lower Css of SCIT PROP, in contrast to the N-
desmethylated metabolite, in CYP2C19 PMs compared to EMs (Paper II and Paper IV) 
indicates that formation of SCIT PROP is more specific for the CYP2C19 enzyme than 
formation of N-desmethyl escitalopram. Furthermore, previous in vivo studies with 
racemic citalopram have reported that the ratio between plasma concentrations of the S- 
and R-enantiomers was 3.5-5.0 for the propionic acid metabolite and 0.6-0.8 for N-
desmethyl citalopram,87;89;95;101;132;133 indicating that propionic acid formation is 
stereoselective for the S-enantiomer. Existence of a metabolic pathway specific for 
CYP2C19 with preference for the S-enantiomer is supported by previous 
pharmacogenetic93 and drug-drug interaction95;132 studies where impaired CYP2C19 
activity has been associated with increased S/R ratios of the parent compound. 
In Figure 4, a summary of the phase I metabolism of escitalopram is illustrated 
based on the present work (Paper I, II and IV) and previous in vivo studies.92-99 
CYP2C19-catalysed formation of N-desmethyl escitalopram and SCIT PROP appears to 
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be the primary elimination pathways of escitalopram in CYP2C19 EMs and UMs. 
Escitalopram is eliminated by N-desmethylation and SCIT PROP formation in CYP2C19 
PMs as well, but alternative pathways are probably of greater importance in these 
subjects.  
4.2 Impact of CYP2C19 genetics on the pharmacokinetic variability of sertraline  
CYP2C19 PMs obtained a 3.2-fold higher Css of sertraline compared to CYP2C19 EMs 
(Paper III). CYP2C19 catalyses both N-desmethylation and direct deamination of 
sertraline (Figure 5),108 and impaired enzyme activity may affect both these metabolic 
pathways. As the bioavailability of sertraline is estimated to be about 45%,106 the higher 
Css was possibly a result of both higher bioavailability and lower clearance in CYP2C19 
PMs compared to EMs.130 
Apart from a report on higher-than-average plasma concentrations in two 
CYP2C19 PMs,138 the study presented in Paper III seems to be the first to investigate the 
pharmacokinetics of sertraline in relation to CYP2C19 genotype at steady state. However, 
a single dose study in 12 healthy Chinese volunteers has previously been performed.117 In 
this study, a 1.4-fold higher AUC of sertraline was observed in CYP2C19 PMs compared 
to CYP2C19 EMs (p<0.05). One possible reason for the different effect size in the study 
presented in Paper III and the study by Wang et al. may be differences in the 
pharmacokinetics of sertraline following single and multiple dosing. Furthermore, 
inclusion of subjects heterozygous for defective CYP2C19 alleles in the reference group 
may also be a reason for the less pronounced difference between CYP2C19 EMs and PMs 
in the study by Wang et al. Based on the work by Wang et al. and in vitro 
data,108;114;116;117 it has been assumed that genetic variability in CYP2C19 is of minor 
importance for the systemic exposure of sertraline.63;139 However, this should be 
reconsidered in light of the findings in the study presented in Paper III. 
Compared to escitalopram, genetic variability in CYP2C19 influenced Css of 
sertraline to a lesser extent. This was expressed both as a less pronounced difference in 
Css between CYP2C19 EMs and PMs and by the absence of effect of the CYP2C19*17 
allele. This possibly reflects that clearance of sertraline in CYP2C19 EMs to a lesser 
degree is mediated by CYP2C19. On the other hand, sertraline has a higher hepatic 
extraction ratio than escitalopram.97;106;129 As clearance of drugs with a high hepatic 
extraction ratio is limited by hepatic blood flow rather than the intrinsic clearance, the 
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difference in extraction ratio might also be a reason for the different impact of genetic 
variability in CYP2C19 on Css of the two drugs. 
Like for the parent compound, Css of N-desmethyl sertraline was higher in the 
subgroups of patients carrying defective CYP2C19 alleles (Paper III). The in vitro study 
by Obach et al. showed that CYP2C19 catalyses the deamination of N-desmethyl 
sertraline to sertraline ketone,108 and the higher Css of N-desmethyl sertraline in 
CYP2C19 PMs was therefore likely due to lower clearance of this metabolite. 
Furthermore, the results of the in vitro study108 indicated that direct deamination of 
sertraline to sertraline ketone is more specific for CYP2C19 than the N-desmethylation. 
Thus, higher Css of N-desmethyl sertraline in CYP2C19 PMs may also be due to a shift in 
sertraline metabolism from direct deamination to the N-desmethylation pathway (Figure 
5). 
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The higher Css of N-desmethyl sertraline in CYP2C19 PMs was in contrast to the study 
by Wang et al., reporting 35% lower AUC of this metabolite in CYP2C19 PMs compared 
to EMs.117 Like for the parent compound, the discrepancies between the two studies may 
be due to differences in composition of the EM groups as well as potential differences in 
the pharmacokinetics following single and multiple drug dosing. Furthermore, measuring 
N-desmethyl sertraline up to 144 hours post dose in the study by Wang et al. may be 
insufficient, as N-desmethyl sertraline is reported to have half-life up to 200 hours.104 
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4.3 Additional contributors to the pharmacokinetic variability of escitalopram 
and sertraline 
4.3.1  CYP2D6 and CYP2C9 
For both escitalopram and sertraline, there was a considerable variability in dose-adjusted 
serum concentrations within the same CYP2C19 genotype. In Paper II and III additional 
factors contributing to pharmacokinetic variability of escitalopram and sertraline were 
identified by covariate analyses in the mixed model approach. For escitalopram, carriers 
of defective CYP2D6 alleles obtained higher Css than patients homozygous for functional 
CYP2D6 alleles (28%). This is consistent with in vitro studies showing that CYP2D6 
catalyses the formation of the N-desmethyl and N-oxide metabolites of escitalopram.90;91 
However, pharmacogenetic studies have reported that impaired CYP2D6 activity is of 
minor importance for the systemic exposure of this drug in vivo.93;97 Nevertheless, it is 
possible that CYP2D6-mediated metabolism of escitalopram is of importance primarily in 
subjects with impaired CYP2C19 activity. This hypothesis was investigated using the 
study population from Paper II supplemented with new data from the TDM database. 
Patients were separated by CYP2C19 genotype (CYP2C19*1/*1, CYP2C19*1/def and 
CYP2C19def/def), and further subdivided according to CYP2D6 genotype 
(CYP2D6*1/*1, CYP2D6*1/def and CYP2D6def/def). The effect of CYP2D6 genotype on 
Css of escitalopram was assessed within each CYP2C19 genotype subgroup (Figure 6). 
Whereas Css of escitalopram was unaffected by CYP2D6 genotype within the 
CYP2C19*1/*1 subgroup (Figure 6A), a 1.4-fold higher Css was observed among carriers 
of the CYP2D6*1/def genotype within the CYP2C19*1/def subgroup (Figure 6B, 
p=0.041). Within the CYP2C19def/def group, similar Css of escitalopram was observed in 
carriers of CYP2D6*1/*1 and CYP2D6*1/def genotypes (Figure 6C), but it should be 
noted that the number of observations were limited compared to the two other CYP2C19 
genotypes. Noteworthy, one of the highest dose-adjusted serum concentrations was 
observed in the single patient with a combined CYP2C19/CYP2D6 PM phenotype, and in 
line with a recent report on racemic citalopram,140 CYP2D6 genetics primarily appears to 
be of importance in patients with impaired CYP2C19 metabolism. Thus, the higher Css 
associated with defective CYP2D6 alleles in the study presented in Paper II was likely 
due to an effect in patients carrying defective CYP2C19 alleles. 
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Figure 6 Dose-adjusted serum concentrations of escitalopram (n=353) in relation to CYP2D6 genotype in 
patients (n=194) carrying the A: CYP2C19*1/*1, B: CYP2C19*1/def, and C: CYP2C19def/def genotype.  
Lines indicate geometric mean values estimated in mixed model analyses. def indicates defective allele. 
 
CYP genotyping also included analyses of variant alleles encoding decreased activity of 
CYP2C9 (i.e. CYP2C9*2, *3 and *5).16 However, despite previous studies reporting that 
CYP2C9 catalyses N-desmethylation of sertraline in vitro,108;114-116 presence of variant 
alleles encoding reduced CYP2C9 activity did not influence Css of sertraline or N-
desmethyl sertraline in the study presented in Paper III. However, CYP2C9 variant alleles 
were co-inherited with alleles encoding functional CYP2C19 activity (Paper II and Paper 
III).141;142 Thus, it is possible that use of a CYP2C9 inhibitor influences metabolism of 
sertraline in subjects with impaired CYP2C19 activity, although this is not detected in 
pharmacogenetic studies due to the relative absence of subjects with genetically impaired 
activity in both enzymes.  
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4.3.2 Gender and age 
In the study presented in Paper II females obtained higher Css of escitalopram than males. 
One possible explanation for this is concurrent use of oral contraceptives, which are 
reported to inhibit CYP2C19 activity.143-145 Although the requisition forms were screened 
for potentially interacting drugs, it cannot be ruled out that non-reported use of oral 
contraceptives contributed to the higher Css of escitalopram in females. Alternatively, 
since clearance of escitalopram is reported to increase with increasing body weight,96 it is 
possible that the observed gender difference was secondary to a most likely lower body 
weight in females than in males. A true gender difference in hepatic CYP2C19 activity is 
controversial, as studies addressing this topic have reported conflicting results.12;143-148
In the study presented in Paper III, patients aged 70 years obtained higher Css of 
sertraline and N-desmethyl sertraline than younger patients (<70 years). This was in 
accordance with previous reports,104;107;109;149 and possibly reflects lower hepatic 
CYP2C19 activity or reduced hepatic blood flow with increasing age.3;147;148;150;151 The 
potential effect of age on Css of escitalopram was not assessed, as the study population in 
Paper II included only a limited number of elderly patients. However, higher systemic 
exposure of escitalopram has been reported in elderly patients in previous studies.96;126;152  
4.3.3  Factors not investigated 
In the study presented in Paper II, dose-adjusted serum concentrations of escitalopram 
appeared to vary less within the subgroups of CYP2C19 UMs and PMs compared to 
CYP2C19 EMs (Figure 1a in Paper II). This was confirmed by assessing the coefficient 
of variation in CYP2C19 UMs, EMs and PMs, which was 36%, 78% and 21%, 
respectively. Likewise, the coefficient of variation for dose-adjusted serum concentrations 
of sertraline was lower within the CYP2C19 PM group compared to EMs (45% vs. 75%, 
respectively). A similar tendency was reported for AUC of escitalopram in the study by 
Ohlsson Rosenborg et al.127 and is also evident from studies with other CYP2C19 
substrates (omeprazole and S-mephenytoin).43;50;52;153 The relative homogeneity in 
phenotype within CYP2C19 UMs and PMs suggests that genetic variability affected the 
allele classified as CYP2C19*1 in these studies. Variant alleles encoding defective or 
reduced CYP2C19 activity other than those analysed have been identified,31;32;48;53;54 as 
well as genetic variability in regulatory regions besides *17 possibly affecting the 
constitutive expression of the CYP2C19 gene and/or its response to environmental 
factors.46;48;49;154;155 
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Sertraline and escitalopram are reported to be substrates for other CYP enzymes, 
for example CYP3A4 and CYP2B6 (only sertraline), and the efflux transporter P-
glycoprotein.90;91;108;114-116;128;156-158 The latter plays a protective role against potential 
toxic substances by limiting their absorption from the intestine, and may therefore affect 
bioavailability of certain drugs.159 The activity of CYP3A4, CYP2B6 and P-glycoprotein 
shows extensive individual variability, due to genetic, physiological and environmental 
factors,2;159;160 and have most likely contributed to the observed variability in serum 
concentrations of escitalopram and sertraline.94;118;119;161-163 Nevertheless, the present 
work shows that genetic variability CYP2C19 is an important pharmacokinetic 
determinant of both escitalopram and sertraline. 
4.4 Impact of the CYP2C19*17 allele on CYP2C19 phenotype
The CYP2C19*17 allele had a less pronounced influence on Css of escitalopram and 
sertraline than the defective CYP2C19 alleles (Paper II and III). This is consistent with 
previous studies with omeprazole and imipramine in Caucasians.43;50;164 In contrast, the 
difference in S/R ratio of mephenytoin has been reported to be of similar magnitude for 
CYP2C19 UMs and PMs compared to CYP2C19 EMs.43;51;52 However, the studies on 
mephenytoin were performed in African populations, where CYP2C19 EMs are reported 
to exhibit lower CYP2C19 activity than EMs of Caucasian origin.50-52;165;166 Hence, the 
apparent difference in relative importance of the CYP2C19 variant alleles between the 
mentioned CYP2C19 substrates might be due to inter-study differences in CYP2C19 
enzyme activity in the EM subgroups. A true substrate difference in the relative 
importance of CYP2C19*17 seems less probable, as the variant alleles encode altered 
amount of active enzyme rather than enzyme with qualitatively altered catalytic 
activity.16;33;34;43 
The term ‘ultrarapid’ was introduced by Sim et al. to denote the phenotype of 
CYP2C19*17/*17 carriers.43 However, the effect of the CYP2C19*17 allele on drug 
exposure might be characterised as moderate as the decrease in systemic exposure in 
homozygous carriers is reported to be less than 2-fold for most drugs investigated (Paper 
II, Paper III).43;127;153;164 Furthermore, the CYP2C19*17/*17 genotype does not seem to 
constitute a separate CYP2C19 phenotype, as there is almost an entire overlap with 
observations in CYP2C19 EMs in most studies (Paper II, Paper III).43;127;153;164 Thus, 
although it seems evident that the CYP2C19*17 allele is associated with a faster-than-
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average metabolism of CYP2C19 substrates, the term ‘ultrarapid’ may overstate the 
phenotypic importance of the CYP2C19*17 allele. 
4.5 Clinical relevance of the findings 
The impact of CYP2C19 genotype was particularly pronounced for escitalopram, where 
CYP2C19 PMs displayed almost 10-fold higher Css than CYP2C19 UMs. In order to 
obtain a systemic exposure of escitalopram comparable to that of an average CYP2C19 
EM patient, CYP2C19 UMs would need a 1.5- to 2-fold higher dose. On the other hand, 
CYP2C19 PMs require on average less than one fifth the dose of an average CYP2C19 
EM patient. Thus, founded on the principle that drug dose is of importance for the 
therapeutic response, it seems reasonable to assume that CYP2C19 genotype would affect 
the clinical response to escitalopram if patients from various subgroups are given equal 
doses. The present work suggests that CYP2C19 UMs might constitute a subgroup of 
patients at increased risk of therapeutic failure, whereas CYP2C19 PMs may be at higher 
risk of dose-dependent side effects, or potentially improved antidepressive effect. 
The difference in Css between CYP2C19 genotypes was less pronounced for 
sertraline than for escitalopram. Nevertheless, the more than 3-fold higher Css of 
sertraline in CYP2C19 PMs than in EMs might be of relevance for the clinical effect 
during sertraline treatment. Moreover, CYP2C19 PMs also obtained a 4.5-fold higher Css 
of N-desmethyl sertraline. The low inhibitory potency of N-desmethyl sertraline on 
serotonin reuptake110-113 indicates a limited contribution from this metabolite to the 
serotonergic effects of sertraline treatment. However, N-desmethyl sertraline is reported 
to exhibit dopamine blocking effects up to 60% compared to the parent 
compound.110;112;113 Thus it is possible that in particular the dopaminergic effects of 
sertraline treatment are more pronounced in CYP2C19 PMs than in EMs.65;102;103 
Systematic studies investigating the impact of genetic variability in CYP2C19 on 
therapeutic outcome of treatment with escitalopram or sertraline seem to be absent. 
However, three studies have investigated the association between CYP2C19 genetics and 
response to racemic citalopram,167-169 but none of these provided statistically significant 
relationships between CYP2C19 genotype and clinical response. The studies may not 
have been optimally designed to detect potential differences in therapeutic effect or side 
effects, but the larger study by Peters et al.167 indicates that genetic variability in 
CYP2C19 is of limited importance for the clinical response to racemic citalopram. 
However, as the R-enantiomer of citalopram is reported to antagonise the effect of the S-
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enantiomer during treatment with racemic citalopram,83 it is possible that the higher 
systemic exposure of the S-enantiomer in CYP2C19 PMs during treatment with racemic 
citalopram is of less importance than an equally elevated systemic exposure of the S-
enantiomer during treatment with escitalopram. Thus, further studies are needed to 
elucidate the value of CYP2C19 genotyping in preventing side effects and therapeutic 
failure during treatment with escitalopram and sertraline. 
Genetic factors besides those assessed in the present work are also likely to affect 
clinical response to escitalopram and sertraline. Variable phenotype of P-glycoprotein 
may, due to its expression in the blood-brain barrier,159 influence distribution of these 
drugs into the brain.156-158 Furthermore, genetic differences in molecular targets, i.e. 
pharmacodynamic variability, are possibly of importance for the therapeutic effect and 
side effects of escitalopram and sertraline.170;171 Transcription of the gene encoding the 
serotonin transporter (SLC6A4) is affected by genetic polymorphism in its promoter 
region (5-HTT gene-linked polymorphic region, 5-HTTLPR), which produces a short and 
a long variant of the 5-HTTLPR.172;173 Studies have provided contradictory results 
regarding the impact of the 5-HTTLPR polymorphism for the clinical effect of sertraline 
and escitalopram,174-178 however a recent meta analysis reported that the long variant was 
associated with better response to SSRI treatment as well as lower risk of side effects.179 
Moreover, genetic polymorphism in genes encoding serotonin receptors have been linked 
to clinical response to various SSRIs,171 including escitalopram.180 
Therapeutic effect and side effects of antidepressants have been associated with 
genetic variability in several loci besides those mentioned here, as well as to clinical 
features, including course of illness, co-morbidity, age and gender.170;181;182 In general, 
only small fractions of the overall variability in response have been explained by single 
variables.180;181 In light of this complex nature of the therapeutic response to 
antidepressants, it is suboptimal to assess the impact of variability in isolated factors. The 
‘monogenetic’ approach in most studies is likely to be a reason for the considerable 
inconsistency regarding the impact of pharmacogenetic variability on clinical outcome of 
treatment with SSRIs. Thus, a multivariate approach seems required in order to determine 
to what extent various factors, including genetic variability in CYP2C19, contribute to 
variability in clinical outcome of escitalopram and sertraline treatment.1;182 
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4.6 Methodological considerations  
Genetic variability as a source to differences in drug exposure are increasingly 
recognised. However, as conventional pharmacogenetic studies often include a low 
number of healthy individuals receiving a single drug dosage, their applicability to assist 
dosing of drugs to individual patients is often limited. By use of TDM data it is possible 
to include larger amounts of data from real-world patients to assess the impact of genetic 
polymorphism on the overall pharmacokinetic variability of a drug in a clinical treatment 
setting. The results from such studies are therefore valuable in the translation of basic 
pharmacogenetic science into practical applications in the clinical everyday life. 
However, the use of TDM data is associated with some methodological weaknesses, such 
as lack of compliance control, variable sampling time, incomplete information on the 
requisition forms, different drug doses, and use of single point measurements. Hence, the 
extensive variability in dose-adjusted serum concentrations in the present work might to 
some degree be due to the naturalistic nature of the data material. This could increase the 
risk of type II errors, i.e. false negative results. However, it is less likely to provide false 
positive associations between CYP2C19 genotype and pharmacokinetics of escitalopram 
and sertraline (type I errors). 
The impact of CYP2C19 genetics on Css of escitalopram was more pronounced in 
the study presented in Paper II than in other studies which have investigated steady state 
pharmacokinetics of escitalopram in relation to CYP2C19 activity (see section 
4.1).92;93;96;97;127 Some of these studies92;93;127 assessed systemic exposure of escitalopram 
in terms of AUC. However inspection of the concentration versus time curves indicated 
that use of trough concentrations instead of AUC would provide similar differences 
between the studies. Another potential explanation for the reported discrepancies in the 
quantitative impact of CYP2C19 genotype is differences in study populations. The other 
studies were controlled pharmacokinetic studies, whereas the study presented in Paper II 
was based on data from TDM. As TDM and CYP genotyping are not routinely carried out 
for all patients receiving treatment with SSRIs, it is possible that these analyses are 
performed more often in clinically problematic cases, i.e. patients experiencing 
therapeutic failure or side effects, than in other patients. As drug exposure is one of the 
factors assumed to be of importance for treatment outcome, one might speculate whether 
the TDM database comprises an overrepresentation of patients with serum concentrations 
at both extremes (very high PMs or very low UMs). If so, the use of TDM data might 
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result in an overestimation of the effect sizes in these outmost CYP2C19 genotypes. Thus, 
further studies are necessary in order to investigate to which degree the effect sizes 
estimated from TDM data are representative for the differences in serum concentrations 
between CYP2C19 genotypes in the general population of patients treated with 
escitalopram and sertraline. Nevertheless, the studies presented in Paper II and Paper III 
showed that, in a naturalistic treatment setting, substantial differences in serum 
concentrations of escitalopram and sertraline exist between subgroups of patients carrying 
different CYP2C19 genotypes. 
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5 CONCLUSION 
 
Genetic variability in CYP2C19 is a major determinant of the pharmacokinetics of 
escitalopram in psychiatric patients, with an almost 10-fold difference in mean dose-
adjusted serum concentration between CYP2C19 UMs and PMs. Besides the well known 
N-desmethylation of escitalopram, CYP2C19 is able to catalyse formation of the 
propionic acid metabolite, and it appears that the differences in serum concentration of 
escitalopram between CYP2C19 genotypes are caused by a combined effect on the two 
metabolic pathways. CYP2C19 genetics is an important determinant of the 
pharmacokinetics of sertraline as well, but the difference in mean dose-adjusted serum 
concentration between CYP2C19 genotypes is less pronounced compared to escitalopram. 
The substantial differences in pharmacokinetics of escitalopram and sertraline 
between CYP2C19 genotypes might be related to the individual’s risk of adverse effects 
and therapeutic failure during treatment with these drugs, and the findings in the present 
thesis may provide a fundament for individual dosing of these drugs. 
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